Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Debiopharm International SA
Sponsor:
Information provided by (Responsible Party):
Debiopharm International SA
ClinicalTrials.gov Identifier:
NCT01948297
First received: August 26, 2013
Last updated: March 21, 2017
Last verified: March 2017

August 26, 2013
March 21, 2017
August 2013
July 2017   (Final data collection date for primary outcome measure)
  • Part A: Percentage of participants with dose-limiting toxicities (DLTs) from Debio 1347 [ Time Frame: within approximately 18 months ]
  • Part B: Percentage of participants with treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: within 2 years of starting treatment ]
  • Part B: Percentage of participants with treatment-emergent adverse events (AEs) and laboratory abnormalities [ Time Frame: within 2 years of starting treatment ]
  • Part B: Severity of treatment-emergent AEs and laboratory abnormalities [ Time Frame: within 2 years of starting treatment ]
    Categories: NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4 severity criteria
Incidence rate of dose limiting toxicities (DLTs) of Debio 1347 [ Time Frame: Approximately 18 months ]
The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.
Complete list of historical versions of study NCT01948297 on ClinicalTrials.gov Archive Site
  • Part A: Percentage of participants with treatment-emergent AEs and laboratory abnormalities [ Time Frame: within 2 years of starting treatment ]
  • Part A: Severity of treatment-emergent AEs and laboratory abnormalities [ Time Frame: within 2 years of starting treatment ]
    Categories: NCI-CTCAE version 4 severity criteria
  • Part A and Part B: Percentage of participants with treatment discontinuations or modifications due to AEs and laboratory abnormalities [ Time Frame: within 2 years of starting treatment ]
  • Part A and Part B: Number of participants with change from baseline in vital signs [ Time Frame: within 2 years of starting treatment ]
    Categories: Electrocardiogram (ECG), Left ventricular ejection fraction (LVEF) and Eastern Cooperative Oncology Group Performance Status (ECOG PS)
  • Part A and Part B: Percentage of participants with tumour response, according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 criteria [ Time Frame: within 2 years of starting treatment ]
    Categories: Overall response, disease control, tumour size
  • Part A and Part B: Number of participants with progression-free survival after treatment initiation [ Time Frame: within 2 years of starting treatment ]
    Categories: overall, 6 months, 1 year, 2 years
  • Part A and Part B: Number of participants with changes in ophthalmological exams [ Time Frame: within 2 years of starting treatment ]
  • Part A and Part B: Maximum concentration (Cmax) of Debio1347 in the pharmacokinetic (PK) subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Time to maximum concentration (tmax) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Apparent terminal half-life (t½) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Area under the concentration versus time curve from the beginning to a point in time (AUC0-t) for Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Area under the plasma concentration-time curve over the dosing interval (AUCt) for Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A: Area under the plasma concentration-time curve extrapolated to infinity (AUC∞) for Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Apparent terminal elimination rate constant (λz) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Mean residence time (MRT) for Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Apparent total body clearance (CL/F) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Apparent volume of distribution during the terminal phase (Vz/F) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Peak-to-Trough fluctuation (PTF) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A and Part B: Average steady-state concentration (Css av) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A: Accumulation ratio (RAUC) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A: Cmax ratio (RCmax) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A: Trough concentration (Ctrough) of Debio1347 in the PK subset [ Time Frame: after 28 days of continuous dosing ]
  • Part A: Estimated relative oral bioavailability of Debio1347 [ Time Frame: after 28 days of continuous dosing ]
    Categories: Tablet, Capsule
  • Part B: Cumulative amount of Debio1347 excreted in urine at steady-state (Ae) in the PK subset [ Time Frame: on Day 28 ]
  • Part B: Percentage of the dose of Debio1347 administered excreted in urine at steady-state (Ae%) in the PK subset [ Time Frame: on Day 28 ]
  • Part B: Renal clearance (CLR) of Debio1347 at steady-state in the PK subset [ Time Frame: on Day 28 ]
  • Part A and Part B: Ctrough of Debio1347 in all participants [ Time Frame: within 2 years of starting treatment ]
  • Safety and tolerability of Debio 1347 combination at the recommended dose (RDE) for expansion [ Time Frame: Every 28 days from baseline visit to 28 days after study drug discontinuation ]
    This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions
  • Markers of FGFR inhibition (FGF-23 and FGF-2) in plasma and tumor [ Time Frame: Baseline and day 8 ]
  • Time vs. concentration profile of Debio 1347 [ Time Frame: Every 28 days for up to the end of the study ]
    Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of Debio 1347
Not Provided
Overall response rate [ Time Frame: Every 8 weeks from the date of baseline visit ]
Assessment of preliminary antitumor activity of Debio 1347; Overall response rate = complete response + partial response
 
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes

This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated.

The main objective of Part A is to identify the dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose (MTD) based on the safety and tolerability of Debio1347 orally administered daily to these patients, in order to determine the recommended dose.

The main objective of Part B is to evaluate the safety profile at the recommended dose, in a larger cohort of these patients.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Solid Tumours
Drug: Debio1347 (CH5183284)
Debio1347 (CH5183284) capsules or tablets for oral administration
Other Name: CH5183284
  • Experimental: Part A
    Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
    Intervention: Drug: Debio1347 (CH5183284)
  • Experimental: Part B
    Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
    Intervention: Drug: Debio1347 (CH5183284)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
112
December 2017
July 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Meets protocol-specified criteria for qualification and contraception
  • Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications
  • Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures

Exclusion Criteria:

  • Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters
  • Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
    3. the analysis of results
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Claudio Zanna, MD +41213210111
United States,   Spain
 
 
NCT01948297
Debio 1347-101
2013-000316-19 ( EudraCT Number )
No
Not Provided
Not Provided
Not Provided
Debiopharm International SA
Debiopharm International SA
Not Provided
Not Provided
Debiopharm International SA
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP